Medicus Pharma appoints Andrew Smith COO; Phase 2 BCC trial randomized >50 of 90 patients

Medicus Pharma Ltd.

Andrew Smith appointed COO effective June 30, 2025; base salary $325K, 100k stock options at $2.60 vesting quarterly over 5 years.
Phase 2 SKNJCT-003 for BCC using D-MNA has randomized >50 of 90 patients across 9 US sites; interim analysis showed >60% clinical clearance (preliminary).
Clinical expansion: European sites plus UAE study SKNJCT-004 (36 patients, 4 sites); Cleveland Clinic Abu Dhabi as PI.
Previously announced binding LOI to acquire Antev Ltd. for Teverelix GnRH antagonist; no new terms disclosed.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Smith

Chief Operating Officer

MDCX · Medicus Pharma Ltd.

Effective: 2025-06-30
Filed: June 23, 2025, 7:59 PM ET

On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO").

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Smith was appointed as Chief Operating Officer at Medicus Pharma Ltd..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO").

View on SEC.gov

Medicus Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001062993-25-012044

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.